Skip to main content
Funded Studies

Jean-Marc Taymans, PhD/IR

Associate Professor at Jean-Pierre Aubert Research Center

Location: Lille France

Jean-Marc Taymans, PhD/Ir, is a Bio-engineer from the KU Leuven (Belgium, 1994). He started his professional career as a vaccine process engineer at SmithKline-Beecham Biologicals (Rixensart, Belgium, 1995-99) before starting PhD research at the graduate school of Neurosciences in Amsterdam (Free University of Amsterdam). He performed his doctoral research in the research labs of Johnson & Johnson Pharmaceutical Research and Development (Beerse, Belgium, 1999-2003), studying schizophrenia-related proteins in the basal ganglia.

In 2004 Dr. Taymans joined the KU Leuven to research the molecular pathogenesis of Parkinson’s disease genes. From 2009-2010 he was a Fulbright scholar at the National Institutes of Health, working with Dr. Mark R. Cookson. He joined the Jean-Pierre Aubert Research Center in Lille (France), a mixed Inserm - Université de Lille - Lille University Hospital center, in October 2014 to further develop PD protein signaling studies while integrating clinical translation of experimental findings in patient biosamples. In September 2017, he was appointed Associate Professor in Neuroscience at the Université de Lille.

Dr. Taymans’s research has focused since 2004 on the cellular signaling processes of LRRK2, using a multidisciplinary approach from biochemical analysis to cellular models to in vivo validation in models and the application of this knowledge to therapeutic and clinical biomarker applications.

Associated Grants

  • Targeting the LRRK2-PAK6 Pathway in Parkinson's Disease


  • Validation of Cyclin-G Associated kinase (GAK) as a Target for Parkinson's Disease


  • Rab Detection Initiative and LRRK2 Detection Initiative Supplemental Support RDI, and LCC exosome replication


  • LRRK2 Biomarker Initiative: Detection of LRRK2 in Cerebrospinal Fluid


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.